Castle Biosciences Inc is a leading healthcare company based in the United States, specializing in dermatological cancer treatment. With an ESG score of 21.3, the company is considered to have a medium risk rating. Castle Biosciences focuses on offering personalized genomic information to help physicians and patients make more precise treatment choices. Their product line includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among other innovative solutions.